PD-1-silenced anti-CD19 CAR T-cell therapy (Sangamo Therapeutics)

N/A

Report date: 2025/06/11 10:39:54

Base Information

Drug NamePD-1-silenced anti-CD19 CAR T-cell therapy (Sangamo Therapeutics)
Drug Alias NamePD-1 ZF-R CAR-T cell therapyanti-CD19 CAR T-cell therapy (Sangamo Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunostimulantsT lymphocytes stimulantsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSangamo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSangamo Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A